Literature DB >> 2406342

Specificity and inhibitory activity of antibodies to Plasmodium falciparum aldolase.

I K Srivastava1, M Schmidt, U Certa, H Döbeli, L H Perrin.   

Abstract

The multiplication of Plasmodium falciparum within RBC is energy-dependent and the glucose consumption of infected RBC is increased more than 50 times over the consumption of normal RBC. High levels of glycolytic enzymes such as fructose-1,6-diphosphate aldolase (p41) have been detected in infected RBC. Expression of the cloned aldolase gene of P. falciparum in Escherichia coli resulted in an enzymatically active polypeptide with a high sp. act. and the recombinant p41 aldolase was used for enzymatic and immunologic studies reported here. The presence of antibodies against p41 in the sera of human adults partially immune to malaria and immunization experiments in monkeys suggest that p41 is implicated in protective immune response against the parasite. Therefore, we analyzed the capacity of various antisera to inhibit P. falciparum aldolase activity. It was found that anti-p41 antibodies raised in mice, rabbits, and monkeys inhibited very efficiently aldolase activity in vitro up to dilutions higher than 10(-3). In contrast none of the human sera with high levels of anti-p41 antibodies were able to inhibit parasite aldolase activity even at a dilution of 1/2. The inability of human antisera to neutralize parasite aldolase is not related to antibody titers but is probably related to the specificity of the human antibodies. This finding is discussed in relation to homology of structure of P. falciparum and mammalian aldolase and to a possible mechanism of parasite adaptation and survival in its natural host.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406342

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins.

Authors:  S Herrera; M A Herrera; B L Perlaza; Y Burki; P Caspers; H Döbeli; D Rotmann; U Certa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 4.  Recent Advances in the Development of Biosensors for Malaria Diagnosis.

Authors:  Francis D Krampa; Yaw Aniweh; Prosper Kanyong; Gordon A Awandare
Journal:  Sensors (Basel)       Date:  2020-02-01       Impact factor: 3.576

5.  Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.

Authors:  Reema Gupta; Vikash Kumar; Pramod Kumar Kushawaha; Chandradev Pati Tripathi; Sumit Joshi; Amogh Anant Sahasrabuddhe; Kalyan Mitra; Shyam Sundar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

Review 6.  Potential biomarkers and their applications for rapid and reliable detection of malaria.

Authors:  Priyamvada Jain; Babina Chakma; Sanjukta Patra; Pranab Goswami
Journal:  Biomed Res Int       Date:  2014-04-02       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.